Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
- BRAF CUX1-BRAF
- Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5977
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2229
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Vemurafenib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29320312
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Vemurafenib | Sensitivity | true |